Purification and characterization of hepatitis B virus surface antigen particles produced in Drosophila Schneider-2 cells

被引:23
作者
Deml, L
Schirmbeck, R
Reimann, J
Wolf, H
Wagner, R
机构
[1] Univ Regensburg, Klinikum Regensburg, Inst Med Microbiol, D-93053 Regensburg, Germany
[2] Univ Ulm, Inst Med Microbiol & Immunol, D-89069 Ulm, Germany
关键词
Drosophila Schneider-2 cells; HBsAg; expression antigenicity; immunogenicity;
D O I
10.1016/S0166-0934(99)00022-1
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The small surface antigen of hepatitis B virus (HBV) was produced in Drosophila melanogaster Schneider-2 (DS-2) cells transfected stably using an inducible Drosophila metallothionein promoter. Selected clonal DS-2 cell-lines expressed and secreted large quantities of HBsAg particles consisting exclusively of non-glycosylated 25 kDa proteins. HBsAg produced by DS-2 cells had physical and biochemical properties very similar to 22 nm particles derived from the human hepatoma cell-line PLC/PRF/5. DS-2 cell-derived HBsAg particles were purified near homogeneity by a strategy based on protein concentration, precipitation and ultracentrifugation. The resulting HBsAg product was < 98% pure. A single immunisation of BALB/c mice with both DS-2 and yeast-cell derived purified HBsAg particles without adjuvants elicited a substantial humoral antibody and class-I restricted cytotoxic T lymphocyte (CTL) response. Adsorbtion of HBsAg particles to aluminium hydroxide resulted in increased levels of HBsAg-specific antibodies. However, CTLs were not elicited by HBsAg/Alum combinations. Thus, stably transfected DS-2 cells provide a useful source for the production of HBV subviral particles for diagnostic and research purposes as well as for novel vaccine development. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:205 / 217
页数:13
相关论文
共 52 条
[41]   DEVELOPMENT OF AUTOREACTIVE L3T4+ T-CELLS FROM DOUBLE-NEGATIVE (L3T4-/LY-2-) THY-1+ SPLEEN-CELLS OF NORMAL MICE [J].
REIMANN, J ;
BELLAN, A ;
CONRADT, P .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1988, 18 (07) :989-999
[42]   NUCLEIC-ACID VACCINATION PRIMES HEPATITIS-B VIRUS SURFACE ANTIGEN-SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN NONRESPONDER MICE [J].
SCHIRMBECK, R ;
BOHM, W ;
ANDO, K ;
CHISARI, FV ;
REIMANN, J .
JOURNAL OF VIROLOGY, 1995, 69 (10) :5929-5934
[43]  
SCHIRMBECK R, 1995, VACCINE, V13, P857, DOI 10.1016/0264-410X(94)00038-O
[44]   ANTIBODY AND CYTOTOXIC T-CELL RESPONSES TO SOLUBLE HEPATITIS-B VIRUS (HBV) S-ANTIGEN IN MICE - IMPLICATION FOR THE PATHOGENESIS OF HBV-INDUCED HEPATITIS [J].
SCHIRMBECK, R ;
MELBER, K ;
MERTENS, T ;
REIMANN, J .
JOURNAL OF VIROLOGY, 1994, 68 (03) :1418-1425
[45]   IMPROVED IMMUNOGENICITY IN MICE OF A MAMMALIAN CELL-DERIVED RECOMBINANT HEPATITIS-B VACCINE CONTAINING PRE-S-1 AND PRE-S-2 ANTIGENS AS COMPARED WITH CONVENTIONAL YEAST-DERIVED VACCINES [J].
SHOUVAL, D ;
ILAN, Y ;
ADLER, R ;
DEEPEN, R ;
PANET, A ;
EVENCHEN, Z ;
GORECKI, M ;
GERLICH, WH .
VACCINE, 1994, 12 (15) :1453-1459
[46]  
STIBBE W, 1983, DEV BIOL STAND, V54, P33
[47]   HEPATITIS-B VACCINE IN MEDICAL STAFF OF HEMODIALYSIS UNITS - EFFICACY AND SUBTYPE CROSS-PROTECTION [J].
SZMUNESS, W ;
STEVENS, CE ;
HARLEY, EJ ;
ZANG, EA ;
ALTER, HJ ;
TAYLOR, PE ;
DEVERA, A ;
CHEN, GTS ;
KELLNER, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1982, 307 (24) :1481-1486
[48]   A CONTROLLED CLINICAL-TRIAL OF THE EFFICACY OF THE HEPATITIS-B VACCINE (HEPTAVAX-B) - A FINAL REPORT [J].
SZMUNESS, W ;
STEVENS, CE ;
ZANG, EA ;
HARLEY, EJ ;
KELLNER, A .
HEPATOLOGY, 1981, 1 (05) :377-385
[49]   THE HEPATITIS-B VIRUS [J].
TIOLLAIS, P ;
POURCEL, C ;
DEJEAN, A .
NATURE, 1985, 317 (6037) :489-495
[50]   SYNTHESIS AND ASSEMBLY OF HEPATITIS-B VIRUS SURFACE-ANTIGEN PARTICLES IN YEAST [J].
VALENZUELA, P ;
MEDINA, A ;
RUTTER, WJ .
NATURE, 1982, 298 (5872) :347-350